Mathijssen Ron H J, Verweij Jaap, de Bruijn Peter, Loos Walter J, Sparreboom Alex
Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
J Natl Cancer Inst. 2002 Aug 21;94(16):1247-9. doi: 10.1093/jnci/94.16.1247.
St. John's wort (SJW), a widely used herbal product, has been implicated in drug interactions resulting from the induced expression of the cytochrome P450 CYP3A4 isoform. In this study, we determined the effect of SJW on the metabolism of irinotecan, a pro-drug of SN-38 and a known substrate for CYP3A4. Five cancer patients were treated with irinotecan (350 mg/m(2), intravenously) in the presence and absence of SJW (900 mg daily, orally for 18 days) in an unblinded, randomized crossover study design. The plasma levels of the active metabolite SN-38 decreased by 42% (95% confidence interval [CI] = 14% to 70%) following SJW cotreatment with 1.0 micro M x h (95% CI = 0.34 micro M x h to 1.7 micro M x h) versus 1.7 micro M x h (95% CI = 0.83 micro M x h to 2.6 micro M x h) (P =.033, two-sided paired Student's t test). Consequently, the degree of myelosuppression was substantially worse in the absence of SJW. These findings indicate that patients on irinotecan treatment should refrain from taking SJW because plasma levels of SN-38 were dramatically reduced, which may have a deleterious impact on treatment outcome.
圣约翰草(SJW)是一种广泛使用的草药产品,已被认为会因细胞色素P450 CYP3A4同工酶的诱导表达而引发药物相互作用。在本研究中,我们测定了SJW对伊立替康代谢的影响,伊立替康是SN - 38的前体药物,也是已知的CYP3A4底物。在一项非盲、随机交叉研究设计中,对5名癌症患者在有和没有SJW(每日900 mg,口服18天)的情况下给予伊立替康(350 mg/m²,静脉注射)治疗。与1.7微摩尔·小时(95%置信区间[CI]=0.83微摩尔·小时至2.6微摩尔·小时)相比,SJW联合治疗后活性代谢物SN - 38的血浆水平在1.0微摩尔·小时(95% CI = 0.34微摩尔·小时至1.7微摩尔·小时)时下降了42%(95% CI = 14%至70%)(P = 0.033,双侧配对学生t检验)。因此,在没有SJW的情况下骨髓抑制程度明显更严重。这些发现表明,接受伊立替康治疗的患者应避免服用SJW,因为SN - 38的血浆水平会显著降低,这可能会对治疗结果产生有害影响。